Conversely, in the BRCA2 P/LP variant group, three of the eleven women who developed breast cancer were on tamoxifen, compared to eight in the placebo group (RR 0.38; 95% CI 0.06–1.56) [113]. Here, BRCA2 is linked to breast carcinoma.